Simultaneous determination of alflutinib and its active metabolite in human plasma using liquid chromatography–tandem mass spectrometry

This publication has 14 references indexed in Scilit:

• Absolute Bioavailability of Osimertinib in Healthy Adults
  Clinical Pharmacology in Drug Development, 2018
• Kinase inhibitors: the road ahead
  Nature Reviews Drug Discovery, 2018
• Third generation EGFR TKIs: current data and future directions
  Molecular Cancer, 2018
• Development of an UPLC–MS/MS method for quantification of Avitinib (AC0010) and its five metabolites in human cerebrospinal fluid: Application to a study of the blood-brain barrier penetration rate of non-small cell lung cancer patients
  Journal of Pharmaceutical and Biomedical Analysis, 2017
• Liquid chromatography–tandem mass spectrometric assay for the T790M mutant EGFR inhibitor osimertinib (AZD9291) in human plasma
  Journal of Chromatography B, 2016
• Olmutinib: First Global Approval
  Drugs, 2016
• Covalent EGFR Inhibitors: Binding Mechanisms, Synthetic Approaches, and Clinical Profiles
  Archiv der Pharmazie, 2016
• Recent progress on third generation covalent EGFR inhibitors
  Bioorganic & Medicinal Chemistry Letters, 2016
• Osimertinib: First Global Approval
  Drugs, 2016
• The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP
  Proceedings of the National Academy of Sciences, 2008